164
perceived-but they can be improved. Cancer
Biol Ther 2(4 Suppl 1):S134–S139- Gros SJ, Kurschat N, Dohrmann T, Reichelt
U, Dancau AM, Peldschus K, Adam G,
Hoffman RM, Izbicki JR, Kaifi JT (2010)
Effective therapeutic targeting of the overex-
pressed HER-2 receptor in a highly metastatic
orthotopic model of esophageal carcinoma.
Mol Cancer Ther 9(7):2037–2045. https://
doi.org/10.1158/1535-7163.mct-10-0209 - Harada K, Ferdous T, Kobayashi H, Ueyama Y
(2014) Paclitaxel in combination with cetux-
imab exerts antitumor effect by suppressing
NF-kappaB activity in human oral squamous
cell carcinoma cell lines. Int J Oncol
45(6):2439–2445. https://doi.org/10.3892/
ijo.2014.2655 - Karginova O, Siegel MB, Van Swearingen AE,
Deal AM, Adamo B, Sambade MJ, Bazyar S,
Nikolaishvili-Feinberg N, Bash R, O’Neal S,
Sandison K, Parker JS, Santos C, Darr D,
Zamboni W, Lee YZ, Miller CR, Anders CK
(2015) Efficacy of Carboplatin alone and in
combination with ABT888 in intracranial
murine models of BRCA-mutated and BRCA-
wild- type triple-negative breast cancer. Mol
Cancer Ther 14(4):920–930. https://doi.
org/10.1158/1535-7163.mct-14-0474 - Awasthi N, Zhang C, Ruan W, Schwarz MA,
Schwarz RE (2012) Evaluation of poly-
mechanistic antiangiogenic combinations to
enhance cytotoxic therapy response in pan-
creatic cancer. PLoS One 7(6):e38477.
https://doi.org/10.1371/journal.pone.
0038477 - Zamai M, VandeVen M, Farao M, Gratton E,
Ghiglieri A, Castelli MG, Fontana E, D’Argy
R, Fiorino A, Pesenti E, Suarato A, Caiolfa VR
(2003) Camptothecin poly[n-(2-
hydroxypropyl) methacrylamide] copolymers
in antitopoisomerase-I tumor therapy: intratu-
mor release and antitumor efficacy. Mol Cancer
Ther 2(1):29–40
27. Awasthi N, Yen PL, Schwarz MA, Schwarz RE
(2012) The efficacy of a novel, dual PI3K/
mTOR inhibitor NVP-BEZ235 to enhance
chemotherapy and antiangiogenic response in
pancreatic cancer. J Cell Biochem 113(3):784–
791. https://doi.org/10.1002/jcb.23405
28. Awasthi N, Kirane A, Schwarz MA, Toombs
JE, Brekken RA, Schwarz RE (2011) Smac
mimetic-derived augmentation of chemothera-
peutic response in experimental pancreatic can-
cer. BMC Cancer 11:15. https://doi.
org/10.1186/1471-2407-11-15
29. Zhang C, Awasthi N, Schwarz MA, Schwarz
RE (2013) Establishing a peritoneal dissemina-
tion xenograft mouse model for survival out-
come assessment of experimental gastric cancer.
J Surg Res 182(2):227–234. https://doi.
org/10.1016/j.jss.2012.10.052
30. Boonstra JJ, van der Velden AW, Beerens EC,
van Marion R, Morita-Fujimura Y, Matsui Y,
Nishihira T, Tselepis C, Hainaut P, Lowe AW,
Beverloo BH, van Dekken H, Tilanus HW,
Dinjens WN (2007) Mistaken identity of
widely used esophageal adenocarcinoma cell
line TE-7. Cancer Res 67(17):7996–8001.
https://doi.org/10.1158/0008-5472.
can-07-2064
31. Chemotherapy for cancer of the esophagus:
https://www.cancer.org/cancer/esophagus-
cancer/treating/chemotherapy.html
32. Risinger AL, Giles FJ, Mooberry SL (2009)
Microtubule dynamics as a target in oncology.
Cancer Treat Rev 35(3):255–261. https://
doi.org/10.1016/j.ctrv.2008.11.001
33. Rowinsky EK, Cazenave LA, Donehower RC
(1990) Taxol: a novel investigational antimi-
crotubule agent. J Natl Cancer Inst
82(15):1247–1259
34. Stanton RA, Gernert KM, Nettles JH, Aneja R
(2011) Drugs that target dynamic microtu-
bules: a new molecular perspective. Med Res
Rev 31(3):443–481. https://doi.
org/10.1002/med.20242
Md Sazzad Hassan and Urs von Holzen